Kidney international. Supplement最新文献

{"title":"Alport syndrome.","authors":"C. Kashtan","doi":"10.1007/978-3-642-02202-9_295","DOIUrl":"https://doi.org/10.1007/978-3-642-02202-9_295","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":"522 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74711594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New strategies to prevent cardiovascular risk in chronic kidney disease. Proceedings of the Sixth International Conference on Hypertension and the Kidney. February 2008. Madrid, Spain.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":" 111","pages":"S1-99"},"PeriodicalIF":0.0,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28023735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Renal Disease in the Emerging World: Toward Global Health Equity. Proceedings of the Bellagio Conference, March 16-18, 2004, Italy.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":" 98","pages":"S1-94"},"PeriodicalIF":0.0,"publicationDate":"2005-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25751900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.","authors":"Line Skoufos,&nbsp;Nicholas Topley,&nbsp;Laurinda Cooker,&nbsp;Anne Dawnay,&nbsp;David J Millar,&nbsp;Clifford J Holmes,&nbsp;Dirk Faict","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Unlabelled: </strong>The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.</p><p><strong>Background: </strong>The biocompatibility profile of a new peritoneal dialysis (PD) solution (Physioneal 35) was determined using a selection of in vitro assay systems. Physioneal 35 is buffered by a combination of 25 mmol/L bicarbonate and 10 mmol/L lactate, thereby providing a solution with a total of 35 mmol/L of alkali to complement the currently available 25 mmol/L bicarbonate and 15 mmol/L lactate combination solution, Physioneal 40. In addition, the new solution contains a calcium concentration of 1.75 mmol/L rather than 1.25 mmol/L present in Physioneal 40. Physioneal 35 and 40 are manufactured in double chamber bag systems that permit separation of glucose from the buffer during sterilization. When the two chambers are mixed just before patient use, the resulting solution has a neutral pH and reduced glucose degradation content. Physioneal 35 was evaluated for its cytotoxicity potential using a murine fibroblast assay, its acute effect on human neutrophil and human peritoneal mesothelial cell function, and its in vitro potential to form advanced glycation end products (AGE). The biocompatibility characteristics of this new formulation were compared with that of a conventional, lactate-based solution and to that of its parent formulation, Physioneal 40.</p><p><strong>Methods: </strong>Proliferation of murine fibroblasts was determined after exposure to dialysis fluids for 72 hours. Cell viability was assayed by the ability to take up neutral red dye. Human neutrophils were exposed for 15 minutes to dialysis fluids, and their ATP content and phorbol 12-myristate 13-acetate (PMA) stimulated chemiluminescence response was determined as a measure of viability and respiratory burst activity, respectively. Cellular interleukin (IL)-1beta-driven IL-8 synthesis by human mesothelial cells following acute exposure to dialysis fluids was also assessed. Advanced glycation end product formation in the dialysis fluids was measured after 5 and 20 days of incubation with human serum albumin (HSA) as the model protein.</p><p><strong>Results: </strong>In all assays employed, the biocompatibility profile of Physioneal 35 was similar to that of the Physioneal 40 parent formulation. Physioneal 35 showed a significant improvement in biocompatibility performance compared to a pH neutralized conventional lactate-buffered peritoneal dialysis solution in the murine fibroblast assay. In the acute exposure assays, human neutrophil viability and respiratory burst were significantly improved compared with the acidic, conventional solution; however, no statistically significant improvement were seen in mesothelial cells. AGE formation, which is thought to be an important mechanism by which glucose and glucose degradation products cause structural and functional changes of the peritoneal membrane, was si","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":" 88","pages":"S94-9"},"PeriodicalIF":0.0,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24304055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceedings of the Third International Conference on Hypertension and the Kidney, February 2002, Madrid, Spain.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":" ","pages":"S1-87"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27543568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients.","authors":"W. Hagen, M. Födinger, G. Heinz, H. Buchmayer, W. Hörl, G. Sunder-Plassmann","doi":"10.1046/j.1523-1755.2001.07854.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07854.x","url":null,"abstract":"BACKGROUND The total homocysteine (tHcy) plasma level, which is partly determined by the MTHFR 677C-->T genotype, may be associated with vascular disease. We prospectively examined the influence of MTHFR genotypes (677C-->T, 1298A-->C) and tHcy plasma concentration on all cause mortality and graft outcomes of renal transplant recipients. METHODS Baseline tHcy plasma levels of 189 patients (three groups with either the MTHFR 677CC, CT or TT genotype, including 63 patients in each group, were matched for age, gender, body mass index and creatinine clearance at baseline), were obtained between September 1996 and May 1997. Follow-up data (time until return to dialysis therapy, time and cause of death) were collected from April to June 1999. Kaplan-Meier survival estimations were calculated and plotted, the groups (three MTHFR 677C-->T genotype groups, or three MTHFR 1298A-->C genotype groups, or two groups with tHcy plasma levels above/below 15 micromol/L) were compared by log-rank test. Age, gender, body mass index (BMI), time since transplantation, serum creatinine, creatinine clearance, combined MTHFR 677C-->T/1298A-->C genotypes, tHcy, folate and vitamin B12 plasma levels were evaluated with regard to graft and patient survival in a multivariate Cox-proportional hazard regression model. RESULTS During the follow-up period of 2.26 +/- 0.66 years, 9 patients died (5 in the TT, 2 in the CT and 2 in the CC genotype group; P = 0.34) and 22 returned to dialysis treatment (7 in the TT, 9 in the CT and 6 in the CC genotype group; P = 0.65). There was also no influence of MTHFR 1298A-->C genotypes (AA genotype, 114 patients; AC genotype, 64 patients; CC genotype, 11 patients) on patient or graft survival (P = 0.7087 and P = 0.1633, respectively). Two of 93 patients with a tHcy plasma level < or = 15 micromol/L died, in contrast to 7 of 96 patients in the tHcy > 15 micromol/L group, P = 0.0778. Two patients in the low tHcy group had to return to dialysis, in contrast to 20 patients in the high tHcy group (P = 0.0001). In the multivariate model there was no significant predictor of patient survival, and the serum creatinine was the only predictor of graft survival (P < 0.0001). CONCLUSIONS In summary, our study shows that neither MTHFR 677C-->T/1298A-->C genotypes nor hyperhomocysteinemia are independently associated with patient or graft survival following kidney transplantation.","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":"50 1","pages":"S253-7"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78261757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.","authors":"K. Aoyagi, S. Shahrzad, S. Iida, C. Tomida, A. Hirayama, S. Nagase, K. Takemura, A. Koyama, S. Ohba, M. Narita, B. Cohen","doi":"10.1046/j.1523-1755.2001.07842.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07842.x","url":null,"abstract":"BACKGROUND We propose that reactive oxygen and argininosuccinic acid (ASA) form guanidinosuccinic acid (GSA). An alternative to this hypothesis is the so-called guanidine cycle, which consists of a series of hydroxyurea derivatives that serve as intermediates in a pathway leading from urea to GSA. We compare the role of the guanidine cycle to that of nitric oxide (NO) in the synthesis of GSA. METHODS The members of the guanidine cycle (hydroxyurea, hydroxylamine plus homoserine, L-canaline, and L-canavanine) were incubated with isolated rat hepatocytes. The known NO donors, NOR-2, NOC-7, and SIN-1, were incubated with ASA in vitro. Ornithine, arginine, or citrulline, which increase arginine, a precursor of NO, were incubated with isolated rat hepatocytes. GSA was determined by high-performance liquid chromatography. RESULTS None of guanidine cycle members except for urea formed GSA. SIN-1, which generates superoxide and NO formed GSA, but other simple NO donors, did not. Both carboxy-PTIO, a scavenger of NO, and dimethyl sulfoxide, a hydroxyl radical scavenger, completely inhibited GSA synthesis by SIN-1. GSA formation by SIN-1 reached a maximum at 0.5 mmol/L and decreased at higher concentrations. GSA synthesis, stimulated by urea in isolated hepatocytes, was inhibited by ornithine, arginine, or citrulline with ammonia, but not by ornithine without ammonia, where arginine production is limited. CONCLUSION GSA is formed from ASA and the hydroxyl radical. When arginine increased in hepatocytes, GSA synthesis decreased. These data suggest that increased NO, which results from high concentrations of arginine, or SIN-1 scavenges the hydroxyl radical. This may explain the decreased GSA synthesis in inborn errors of the urea cycle where ASA is decreased, and also the diminished GSA excretion in arginemia.","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":"6 1","pages":"S93-6"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75972010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of dialyzer membrane on interleukin-1beta (IL-1beta) and IL-1beta-converting enzyme in mononuclear cells.","authors":"S. Linnenweber, G. Lonnemann","doi":"10.1046/j.1523-1755.2001.07829.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07829.x","url":null,"abstract":"BACKGROUND In vitro stimulation of mononuclear cells (peripheral blood mononuclear cells; PBMCs) with an endotoxin (lipopolysaccharide; LPS) revealed elevated cell-associated levels of interleukin-1beta (IL-1beta) in end-stage renal disease (ESRD) patients on Cuprophan hemodialysis (HD), suggesting a defect in the process of IL-1beta's release from activated cells. IL-1beta is initially synthesized as an inactive precursor called proIL-1beta. ProIL-1beta is processed into the biologically active mature form of IL-1beta (mIL-1beta) requiring the specific IL-1beta-converting enzyme (ICE). METHODS Using specific immunoassays (enzyme-linked immunosorbent assays), we measured cell-associated and extracellular proIL-1beta as well as mIL-1beta in LPS-stimulated PBMCs to test whether ICE-dependent processing of proIL-1beta and/or secretion of mIL-1beta was impaired in ESRD patients compared with healthy controls. PBMCs of healthy controls (N = 9), of ESRD patients on peritoneal dialysis (PD, N = 10), and of those patients on intermittent HD (N = 8) were studied. The same HD patients were studied three times with low-flux Cuprophan (GFS 12), low-flux polysulfon (F6 HPS), and high-flux polysulfon (F60S) in randomized order. PBMCs were separated from whole blood by Ficoll-Hypaque centrifugation and incubated in vitro for 18 hours in the presence LPS (10 ng/mL). Extracellular (PBMC culture supernatants) and cell-associated (cell lysates) levels of proIL-1beta and mIL-1beta were measured. RESULTS The total production (cell-associated plus extracellular) of LPS-induced IL-1beta (proIL-1beta plus mIL-1beta) was similar in healthy controls (25.96 +/- 0.84 ng/2.5 x 10(6) PBMC), PD patients (29.53 +/- 1.31 ng/2.5 x 106 PBMC), and in Cuprophan-treated HD patients (23.28 +/- 1.24 ng/2.5 x 10(6) PBMC). In normal controls, 43.6% of the total IL-1beta was processed into mIL-1beta, which was significantly more than that in PD patients (27.3%, P < 0.02) but was similar to that in Cuprophan-treated HD patients (37.1%). Comparing cell-associated and extracellular concentrations of mIL-1beta, PBMCs of normal controls secreted 82.2% of mIL-1beta; this was significantly more than that in PD patients (59.4%, P < 0.01) and that in Cuprophan HD patients (54.2%, P < 0.01). When HD patients were switched from Cuprophan to F6 HPS or F60S, neither total IL-1beta production nor processing of IL-1beta changed. However, secretion of mIL-1beta increased significantly with F6 HPS (80.6%, P < 0.01) as well as with F60S (76.6%, P < 0.02) compared with Cuprophan. CONCLUSION We conclude that the ability of PBMCs to produce IL-1beta in response to LPS is normal in PD patients as well as in HD patients. ICE-dependent processing of inactive proIL-1beta into biologically active mIL-1beta is reduced in PD patients, but not in HD patients. Secretion of mIL-1beta is impaired in PD and HD patients treated with Cuprophan. This impaired ability to secrete active mIL-1beta seems to be independent","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":"18 4","pages":"S282-5"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91469173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"beta2-microglobulin-derived amyloidosis: an update.","authors":"Jürgen Floege, Markus Ketteler","doi":"10.1046/j.1523-1755.2001.07823.x","DOIUrl":"https://doi.org/10.1046/j.1523-1755.2001.07823.x","url":null,"abstract":"The present review attempts to summarize recent developments in the field of beta2-microglobulin-derived amyloidosis (A(beta2)m amyloidosis) in patients on chronic dialysis therapy. A key factor in the pathogenesis is the uremic retention of the precursor molecule, beta2-microglobulin (beta2m). However, secondary modifications of the molecule such as limited proteolysis, conformational changes, and the formation of advanced glycation end products have also been described. Finally, in order to explain the striking predilection of the disease for synovial and periarticular structures, a role of local predisposing factors within the synovial membrane (for example, of the particular constituents of the extracellular matrix) must also be postulated. With respect to clinical symptomatology, recent data have confirmed that clinically manifest signs of the amyloidosis represent only the tip of the iceberg, since histologically amyloid deposition is much more widespread. Noninvasive diagnosing of the disease has been advanced by technical changes of the beta2m scintigraphy. Finally, there is accumulating evidence that prevention of the disease not only includes the usage of high-flux synthetic membranes for hemodialysis or hemodiafiltration, but that other factors contribute to the clinical manifestations of amyloidosis such as the dialysate composition and its microbacteriological quality. Such factors, which have changed over the last years as part of general improvements in dialysis care, may explain why the prevalence of the amyloidosis appears to decrease.","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":"30 1","pages":"S164-71"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89365690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apoptosis and extracellular matrix-cell interactions in kidney disease.","authors":"H Makino,&nbsp;H Sugiyama,&nbsp;N Kashihara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Apoptosis and extracellular matrix-cell interactions in kidney disease. Extracellular matrix (ECM)-cell interactions have major effects on phenotypic features such as cell growth, differentiation, and gene expression. Apoptosis is an active form of cell death that is crucial for maintaining an appropriate number of cells as well as tissue organization. Recent reports have implied that ECM can influence survival and apoptosis of several cell lineages including glomerular mesangial cells (MC). Numerous glomerular diseases are associated with the expansion of the mesangial ECM, which may eventually produce glomerular scarring. Glomerular cell apoptosis is associated with the deletion of glomerular cells and the accumulation of ECM in the progression of glomerulosclerosis in rat remnant kidney model induced by 5/6 nephrectomy. Our recent study indicated that basement membrane matrix (a model for normal ECM components) prevented cultured MC from undergoing apoptosis after serum deprivation, thus promoting their survival, compared with type I collagen matrix (a model for abnormal ECM components). Inhibition of matrix-derived signals by antisense oligonucleotides against beta1 integrin increased MC apoptosis. Data suggest that the survival and death of MC are regulated by the surrounding ECM through integrin molecules. The mechanism of regulation of MC apoptosis by ECM requires further in vivo study to gain new insight into the treatment of glomerular diseases as well as the pathophysiology of the mesangium. Diabetic nephropathy is characterized by the abnormal ECM accumulation and the phenotypic change of MC. Some speculations on the possible involvement of apoptosis in diabetic nephropathy are also discussed.</p>","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":"77 ","pages":"S67-75"},"PeriodicalIF":0.0,"publicationDate":"2000-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21830488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}